MD-026 is the first RSK inhibitor to demonstrate potential disease-modifying properties in triple-negative breast cancer (TNBC) Vancover, April 19, 2018: Phoenix…
Agreement follows the recent opening of WuXi STA’s oligonucleotide R&D labs in China and the USA. Shanghai, May 03, 2018: STA…